← Back to Home

Cancer Cells Write Messages but Cannot Make Proteins: APOBEC3B Offers Clues to ATR Inhibitor Response

A cell study found that APOBEC3B may cause ATR inhibitors to trigger RNA retention in the nucleus, severing the link between gene activation and protein production. But whether this response promotes cancer cell death or helps cells recover remains a question that must be answered before moving toward patient selection.

By SURL BioNews

After cancer cells come under attack from a drug, even activating response genes may not enable them to produce the proteins needed to cope with the damage. A team at the University of California, Irvine, found that the key may lie in genetic messages becoming trapped in the nucleus. The finding provides a new mechanistic clue to understanding why cancer cells respond differently to ATR inhibitors.

The university described the study, published in *Molecular Cell*, on November 6, noting that the APOBEC3B enzyme helps determine this response. ATR normally helps protect DNA and maintain repair; the research team found that when ATR is inhibited, APOBEC3B can act on unprotected DNA, triggering abnormal activation of the DNA repair protein PARP1.

Message transport is affected next. Messenger RNA carries instructions transcribed from DNA and must leave the nucleus before the machinery that makes proteins can read them. According to the university, overactivated PARP1 causes these RNAs to remain in the nucleus, leaving genes activated but preventing the corresponding proteins from being produced properly.

This also reminds researchers that looking at RNA abundance alone may overestimate the response cells actually carry out. In the cell models the team tested, cancer cells with APOBEC3B showed this PARP1-dependent suppression of protein production; cells lacking APOBEC3B did not show the same response. This difference makes APOBEC3B a candidate biomarker worthy of further validation.

However, identifying a cellular response is still some distance from predicting whether patients will benefit. The research team said that blocking protein production could help damaged cells recover or promote their death, with outcomes potentially varying according to treatment conditions. The presence of APOBEC3B therefore cannot currently be interpreted directly as evidence of greater ATR inhibitor efficacy.

There are also limits to examining the publicly available data. A dataset on Mendeley Data bearing the same title as the study lists Remi Buisson as a contributor, with its first version released on October 8; however, the data description and files are not scheduled to become public until January 7, 2027. Its registration information can currently be checked, but the underlying data cannot yet be independently examined through this dataset.

ATR inhibitors are being studied clinically as single agents or in combination therapies. The team's next step will be to use models that more closely resemble human tumors to establish whether APOBEC3B can reliably predict RNA retention and reduced protein production, and to clarify how cancer cell survival changes when drugs that affect PARP1 are added. These answers will determine whether this mechanism can be translated into a basis for treatment selection.

References

  1. UC Irvine School of Medicine
  2. Mendeley Data